Free Access
Med Sci (Paris)
Volume 25, Number 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1063 - 1069
Section I - De la conception à la production
Published online 15 December 2009
  1. World Cancer Therapies Market : [Google Scholar]
  2. Gonzales NR, De Pascalis R, Schlom J, et al. Minimizing the immunogenicity of antibodies for clinical application. Tumor Biol 2005; 26 : 31–43. [Google Scholar]
  3. Kashmiri SV, De Pascalis R, Gonzales NR, Schlom J. SDR grafting-a new approach to antibody humanization. Methods 2005; 36 : 25–34. [Google Scholar]
  4. Schellekens H. Immunogenicity of therapeutic proteins : clinical implications and future prospects. Clin Ther 2002; 24 : 1720–40. [Google Scholar]
  5. Daugherty AL, Mrsny RJ. Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev 2006; 58 : 686–706. [Google Scholar]
  6. Roskos LK, Davis CG, Schwab GM. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev Res 2004; 61 : 108–20. [Google Scholar]
  7. Cromwell ME, Hilario E, Jacobson F. Protein aggregation and bioprocessing. AAPS J 2006; 8 : E572–9. [Google Scholar]
  8. Wang W, Ang W, Singh S., et al. Antibody Structure, Instability, and Formulation. J Pharm Sci 2007; 96 : 1–26. [Google Scholar]
  9. Chi EY, Krishnan S, Randolph TW, et al. Physical stability of proteins in aqueous solution : mechanism and driving forces in non-native protein aggregation. Pharm Res 2003; 20 : 1325–36. [Google Scholar]
  10. Rosenberg AS. Effects of protein aggregates : an immunologic perspective. AAPS J 2006; 8 : 501–7. [Google Scholar]
  11. Mahler HC, Friess W, Grauschopf U, et al. Protein aggregation : pathways, induction factors and analysis. J Pharm Sci 2009; 98 : 2909–34. [Google Scholar]
  12. Carpenter JF, Randolph TW, Jiskoot W, et al. Overlooking subvisible particles in therapeutic protein products : gaps that may compromise product quality. J Pharm Sci 2009; 98 : 1201–5. [Google Scholar]
  13. Liu H, Gaza-Bulseco G, Faldu D, et al. Heterogeneity of monoclonal antibodies. J Pharm Sci 2008; 97 : 2426–47. [Google Scholar]
  14. Kiese S, Pappenberger A, Friess W, et al. Shaken, not stirred : mechanical stress testing of an IgG1 antibody. J Pharm Sci 2008; 97 : 4347–66. [Google Scholar]
  15. Casadevall N, Nataf J, Viron B, et al. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346 : 469–75. [Google Scholar]
  16. Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high protein concentration formulations. J Pharm Sci 2004; 93 : 1390–1402. [Google Scholar]
  17. Yang MX, Shenoy B, Disttler M, et al. Crystalline monoclonal antibodies for subcutaneous delivery. Proc Natl Acad Sci USA 2003; 100 : 6934–9. [Google Scholar]
  18. Reilly RM, Domingo R, Sandhu J. Oral delivery of antibodies. Future pharmacokinetic trends. Clin Pharmacokinet 1997; 32 : 313–23. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.